Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FBP1 CRISPR Activation Plasmid (h): sc-401293-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FBP1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- FBP1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by FBP1 CRISPR Activation Plasmid (h) and FBP1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FUBP1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FBP1 Antibody (G-8): sc-271241
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FBP1 CRISPR Activation Plasmid (h) | sc-401293-ACT | 20 µg | $397.00 |
Human FUBP1 encodes far upstream element-binding protein 1 (FBP1), a single-stranded nucleic acid–binding regulator that modulates transcriptional and post-transcriptional programs by interacting with promoter-associated elements and RNA targets. FBP1 is best known for influencing MYC expression and broader gene networks that govern cell-cycle progression, proliferation, and stress-adaptive responses. Through these activities, FUBP1 connects to pathways controlling chromatin-associated transcriptional regulation and RNA metabolism, making it a key node for studying context-dependent gene expression. Altered FUBP1 activity or dosage has been reported in multiple cancer- and neurodevelopment-relevant settings, supporting its use in mechanistic models of oncogenic signaling, differentiation, and genome stability.
FBP1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FUBP1 expression without altering the underlying DNA sequence.
FBP1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FUBP1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FUBP1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FBP1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FUBP1 locus and enabling the study of FBP1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FBP1 pathway restoration in tumor cells with silenced or reduced FUBP1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.